» Articles » PMID: 35967342

Proposed Clinical Phases for the Improvement of Personalized Treatment of Checkpoint Inhibitor-related Pneumonitis

Abstract

Background: Checkpoint inhibitor-related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined.

Methods: We conducted a multicenter retrospective analysis of 56 patients who developed CIP. Clinical characteristics, radiological features, histologic features, and laboratory tests were analyzed. After a comprehensive analysis, we proposed acute, subacute, and chronic phases of CIP and summarized each phase's characteristics.

Results: There were 51 patients in the acute phase, 22 in the subacute phase, and 11 in the chronic phase. The median interval time from the beginning of CIP to the different phases was calculated (acute phase: ≤4.9 weeks; subacute phase: 4.9~13.1 weeks; and chronic phase: ≥13.1 weeks). The symptoms relieved from the acute phase to the chronic phase, and the CIP grade and Performance Status score decreased (<0.05). The main change in radiologic features was the absorption of the lesions, and 3 (3/11) patients in the chronic phase had persistent traction bronchiectasis. For histologic features, most patients had acute fibrinous pneumonitis in the acute phase (5/8), and most had organizing pneumonia in the subacute phase (5/6). Other histologic changes advanced over time, with the lesions entering a state of fibrosis. Moreover, the levels of interleukin-6, interleukin-10 and high-sensitivity C-reactive protein (hsCRP) increased in the acute phase and decreased as CIP progressed (IL-6: 17.9 vs. 9.8 vs. 5.7, P=0.018; IL-10: 4.6 vs 3.0 vs. 2.0, P=0.041; hsCRP: 88.2 vs. 19.4 vs. 14.4, P=0.005).

Conclusions: The general development process of CIP can be divided into acute, subacute, and chronic phases, upon which a better management strategy might be based devised.

Citing Articles

Cancer therapy-related interstitial lung disease.

Zhou C, Deng H, Yang Y, Wang F, Lin X, Liu M Chin Med J (Engl). 2024; 138(3):264-277.

PMID: 39402974 PMC: 11771665. DOI: 10.1097/CM9.0000000000003149.


Increased plasma AACT level as an indicator of poor prognosis in patients hospitalised with community-acquired pneumonia: a multicentre prospective cohort study.

Zhao L, Xi W, Shang Y, Gao W, Bian W, Chen X BMC Infect Dis. 2024; 24(1):946.

PMID: 39251931 PMC: 11384707. DOI: 10.1186/s12879-024-09742-x.


Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management.

Lin M, Zang D, Liu C, Han X, Chen J Front Immunol. 2024; 15:1266850.

PMID: 38426102 PMC: 10902117. DOI: 10.3389/fimmu.2024.1266850.


Pulmonary toxicity of immune checkpoint immunotherapy.

Ghanbar M, Suresh K J Clin Invest. 2024; 134(2).

PMID: 38226621 PMC: 10786690. DOI: 10.1172/JCI170503.


Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).

Hu X, Ren J, Xue Q, Luan R, Ding D, Tan J Int J Oncol. 2023; 63(5).

PMID: 37681488 PMC: 10552702. DOI: 10.3892/ijo.2023.5570.


References
1.
Cadranel J, Canellas A, Matton L, Darrason M, Parrot A, Naccache J . Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. Eur Respir Rev. 2019; 28(153). PMC: 9488121. DOI: 10.1183/16000617.0058-2019. View

2.
Gifford A, Matsuoka M, Ghoda L, Homer R, Enelow R . Chronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes. Mucosal Immunol. 2012; 5(5):480-4. DOI: 10.1038/mi.2012.68. View

3.
Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B . Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020; 17(8):504-515. DOI: 10.1038/s41571-020-0352-8. View

4.
Nishino M, Ramaiya N, Awad M, Sholl L, Maattala J, Taibi M . PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016; 22(24):6051-6060. PMC: 5161686. DOI: 10.1158/1078-0432.CCR-16-1320. View

5.
Suresh K, Voong K, Shankar B, Forde P, Ettinger D, Marrone K . Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. J Thorac Oncol. 2018; 13(12):1930-1939. DOI: 10.1016/j.jtho.2018.08.2035. View